Key Points
- Francisco Partners sold 1,296,177 GoodRx shares at an average price of $3.50, generating approximately $4.54 million. The major shareholder also made several additional sales from August 19–25.
- GoodRx reported quarterly revenue of $200.4 million, above analyst expectations of $193.2 million, while earnings of $0.08 per share matched estimates; revenue declined 1.3% year over year.
- Analyst sentiment remains mixed, with an overall “Hold” rating and an average price target of $4.23. GoodRx shares opened at $3.65, compared with a 52-week range of $1.77 to $5.81.
GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) major shareholder Francisco Partners Iv, L.P. sold 127,273 shares of the business's stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $3.44, for a total transaction of $437,819.12. Following the completion of the transaction, the insider owned 643,466 shares of the company's stock, valued at approximately $2,213,523.04. This represents a 16.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.
Francisco Partners Iv, L.P. also recently made the following trade(s):
- On Wednesday, August 26th, Francisco Partners Iv, L.P. sold 1,296,177 shares of GoodRx stock. The shares were sold at an average price of $3.50, for a total value of $4,536,619.50.
- On Monday, August 24th, Francisco Partners Iv, L.P. sold 143,594 shares of GoodRx stock. The stock was sold at an average price of $3.46, for a total value of $496,835.24.
- On Friday, August 21st, Francisco Partners Iv, L.P. sold 274,717 shares of GoodRx stock. The shares were sold at an average price of $3.50, for a total transaction of $961,509.50.
- On Thursday, August 20th, Francisco Partners Iv, L.P. sold 447,259 shares of GoodRx stock. The shares were sold at an average price of $3.52, for a total transaction of $1,574,351.68.
- On Wednesday, August 19th, Francisco Partners Iv, L.P. sold 471,975 shares of GoodRx stock. The stock was sold at an average price of $3.53, for a total value of $1,666,071.75.
GoodRx Stock Performance
GDRX opened at $3.65 on Thursday. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.74. GoodRx Holdings, Inc. has a twelve month low of $1.77 and a twelve month high of $5.81. The firm's 50-day moving average price is $3.18 and its 200 day moving average price is $2.66. The firm has a market capitalization of $1.25 billion, a PE ratio of 91.27, a PEG ratio of 1.73 and a beta of 1.60.
GoodRx (NASDAQ:GDRX - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.08 EPS for the quarter, meeting the consensus estimate of $0.08. The firm had revenue of $200.41 million for the quarter, compared to analyst estimates of $193.23 million. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The business's revenue for the quarter was down 1.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.09 EPS. As a group, sell-side analysts expect that GoodRx Holdings, Inc. will post 0.16 EPS for the current fiscal year.
Wall Street Analyst Weigh In
GDRX has been the topic of a number of recent research reports. UBS Group boosted their price target on shares of GoodRx from $2.50 to $3.75 and gave the stock a "neutral" rating in a research note on Thursday, August 13th. Barclays boosted their price target on shares of GoodRx from $3.00 to $4.00 and gave the stock an "underweight" rating in a research note on Thursday, August 20th. Wells Fargo & Company increased their price objective on GoodRx from $3.50 to $5.00 and gave the company an "overweight" rating in a research note on Friday, August 7th. Citigroup boosted their target price on GoodRx from $4.00 to $5.00 and gave the stock a "buy" rating in a research note on Tuesday, August 11th. Finally, Weiss Ratings upgraded shares of GoodRx from a "sell (d)" rating to a "sell (d+)" rating in a research report on Friday, August 7th. Four research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $4.23.
Get Our Latest Analysis on GoodRx
Institutional Trading of GoodRx
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Essential Partners LLC lifted its position in shares of GoodRx by 375.4% during the 1st quarter. Essential Partners LLC now owns 14,304 shares of the company's stock valued at $28,000 after acquiring an additional 11,295 shares during the period. Meridian Wealth Management LLC purchased a new position in GoodRx in the 4th quarter valued at about $29,000. SG Americas Securities LLC purchased a new position in shares of GoodRx during the first quarter valued at approximately $29,000. Headlands Technologies LLC acquired a new position in GoodRx in the 2nd quarter valued at $30,000. Finally, Krilogy Financial LLC acquired a new stake in shares of GoodRx during the first quarter worth $33,000. Institutional investors and hedge funds own 63.77% of the company's stock.
About GoodRx
(
Get Free Report)
GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.
In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
